Land: Europäische Union
Sprache: Englisch
Quelle: EMA (European Medicines Agency)
tivozanib
Recordati Netherlands B.V.
L01EK03
tivozanib hydrochloride monohydrate
Antineoplastic agents
Carcinoma, Renal Cell
Fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC. Treatment of advanced renal cell carcinoma.,
Revision: 9
Authorised
2017-08-24
31 B. PACKAGE LEAFLET 32 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT FOTIVDA 890 MICROGRAM HARD CAPSULES FOTIVDA 1340 MICROGRAM HARD CAPSULES tivozanib READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Fotivda is and what it is used for 2. What you need to know before you take Fotivda 3. How to take Fotivda 4. Possible side effects 5. How to store Fotivda 6. Contents of the pack and other information 1. WHAT FOTIVDA IS AND WHAT IT IS USED FOR The active substance in Fotivda is tivozanib, which is a protein kinase inhibitor. Tivozanib reduces the supply of blood to the cancer, which slows down the growth and spread of cancer cells. It works by blocking the action of a protein called vascular endothelial growth factor (VEGF). Blocking the action of VEGF prevents the formation of new blood vessels. Fotivda is used to treat adults with advanced kidney cancer. It is used where other treatments such as interferon-alpha or interleukin-2 have either not yet been used or have not helped to stop your disease. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE FOTIVDA Do not take Fotivda: • If you are allergic to tivozanib or any of the other ingredients of this medicine (listed in section 6); • If you are taking St. John’s Wort (also known as _Hypericum perforatum_ , a herbal remedy used for treatment of depression and anxiety). WARNINGS AND PRECAUTIONS Talk to your doctor, pharmacist or nurse before taking Fotivda: • if you have HIGH BLOOD PRESSURE Fotivda can increase your blood pressure. You Lesen Sie das vollständige Dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Fotivda 890 microgram hard capsules Fotivda 1340 microgram hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Fotivda 890 microgram hard capsules Each hard capsule contains tivozanib hydrochloride monohydrate equivalent to 890 microgram tivozanib. _Excipients with known effect _ Each hard capsule contains trace amounts of tartrazine (E102) (8-12% of the yellow printing ink composition) (see section 4.4). Fotivda 1340 microgram hard capsules Each hard capsule contains tivozanib hydrochloride monohydrate equivalent to 1340 microgram tivozanib. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule. Fotivda 890 microgram hard capsules Hard capsule with dark blue opaque cap and bright yellow opaque body, printed with yellow ink “TIVZ” on the cap and with dark blue ink “LD” on the body. Fotivda 1340 microgram hard capsules Hard capsule with bright yellow opaque cap and bright yellow opaque body, printed with dark blue ink “TIVZ” on the cap and with dark blue ink “SD” on the body. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Fotivda should be supervised by a physician experienced in the use of anticancer therapies. Posology The recommended dose of tivozanib is 1340 microgram once daily for 21 days, followed by a 7-day rest period to comprise one complete treatment cycle of 4 weeks. This treatment schedule should be continued until disease progression or unacceptable toxicity. 3 No more than one dose of Fotivda must be taken per day. _Dose modification _ The occurrence of undesirable effects may require temporary interruption and/or dose reduction of tivozanib therapy ( Lesen Sie das vollständige Dokument